FI20031191A7 - Monoamiinin takaisinoton estäjä - Google Patents

Monoamiinin takaisinoton estäjä Download PDF

Info

Publication number
FI20031191A7
FI20031191A7 FI20031191A FI20031191A FI20031191A7 FI 20031191 A7 FI20031191 A7 FI 20031191A7 FI 20031191 A FI20031191 A FI 20031191A FI 20031191 A FI20031191 A FI 20031191A FI 20031191 A7 FI20031191 A7 FI 20031191A7
Authority
FI
Finland
Prior art keywords
monoamine reuptake
reuptake inhibitor
monoamine
mammals
methods
Prior art date
Application number
FI20031191A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI20031191L (fi
Inventor
David Taiwai Wong
Edward Louis Mattiuz
John-Michael Sauer
William Joe Wheeler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20031191(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI20031191L publication Critical patent/FI20031191L/fi
Publication of FI20031191A7 publication Critical patent/FI20031191A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI20031191A 2001-03-06 2002-02-20 Monoamiinin takaisinoton estäjä FI20031191A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (2)

Publication Number Publication Date
FI20031191L FI20031191L (fi) 2003-08-25
FI20031191A7 true FI20031191A7 (fi) 2003-08-25

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20031191A FI20031191A7 (fi) 2001-03-06 2002-02-20 Monoamiinin takaisinoton estäjä

Country Status (35)

Country Link
US (2) US20040082666A1 (cg-RX-API-DMAC10.html)
EP (1) EP1379492B1 (cg-RX-API-DMAC10.html)
JP (1) JP2004525912A (cg-RX-API-DMAC10.html)
KR (1) KR20030092012A (cg-RX-API-DMAC10.html)
CN (1) CN1229331C (cg-RX-API-DMAC10.html)
AP (1) AP2003002855A0 (cg-RX-API-DMAC10.html)
AT (2) AT414238B (cg-RX-API-DMAC10.html)
AU (1) AU2002245385B2 (cg-RX-API-DMAC10.html)
BR (1) BR0207716A (cg-RX-API-DMAC10.html)
CA (1) CA2440161A1 (cg-RX-API-DMAC10.html)
CH (1) CH695982A5 (cg-RX-API-DMAC10.html)
CZ (1) CZ20032380A3 (cg-RX-API-DMAC10.html)
DE (1) DE60226715D1 (cg-RX-API-DMAC10.html)
DK (1) DK200301267A (cg-RX-API-DMAC10.html)
EA (1) EA005768B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP034760A (cg-RX-API-DMAC10.html)
EE (1) EE200300419A (cg-RX-API-DMAC10.html)
ES (2) ES2305221T3 (cg-RX-API-DMAC10.html)
FI (1) FI20031191A7 (cg-RX-API-DMAC10.html)
GB (1) GB2389851B (cg-RX-API-DMAC10.html)
HR (1) HRP20030710A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0303341A3 (cg-RX-API-DMAC10.html)
IL (1) IL157779A0 (cg-RX-API-DMAC10.html)
LT (1) LT5143B (cg-RX-API-DMAC10.html)
LU (1) LU91038B1 (cg-RX-API-DMAC10.html)
LV (1) LV13119B (cg-RX-API-DMAC10.html)
NO (1) NO20033921L (cg-RX-API-DMAC10.html)
NZ (1) NZ527431A (cg-RX-API-DMAC10.html)
OA (1) OA12494A (cg-RX-API-DMAC10.html)
PL (1) PL363840A1 (cg-RX-API-DMAC10.html)
SE (1) SE526598C2 (cg-RX-API-DMAC10.html)
SK (1) SK10632003A3 (cg-RX-API-DMAC10.html)
TR (1) TR200705146T1 (cg-RX-API-DMAC10.html)
WO (1) WO2002070457A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200306882B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414238B (de) * 2001-03-06 2006-10-15 Lilly Co Eli Neues hydroxyliertes 3-phenoxy-3-phenyl-1- aminopropan und dieses aminopropan enthaltende pharmazeutische formulierung
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
AU3877500A (en) 1999-04-09 2000-11-14 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
AT414238B (de) * 2001-03-06 2006-10-15 Lilly Co Eli Neues hydroxyliertes 3-phenoxy-3-phenyl-1- aminopropan und dieses aminopropan enthaltende pharmazeutische formulierung

Also Published As

Publication number Publication date
SE526598C2 (sv) 2005-10-18
LU91038B1 (fr) 2003-09-11
HUP0303341A2 (hu) 2004-01-28
ES2201942B2 (es) 2004-12-16
NO20033921L (no) 2003-11-05
OA12494A (en) 2006-05-24
AP2003002855A0 (en) 2003-08-20
HRP20030710A2 (en) 2004-08-31
FI20031191L (fi) 2003-08-25
GB2389851A (en) 2003-12-24
EA005768B1 (ru) 2005-06-30
US7384983B2 (en) 2008-06-10
EP1379492B1 (en) 2008-05-21
CH695982A5 (de) 2006-11-15
GB2389851B (en) 2005-05-25
US20040082666A1 (en) 2004-04-29
DE60226715D1 (de) 2008-07-03
CN1494526A (zh) 2004-05-05
BR0207716A (pt) 2004-03-23
ECSP034760A (es) 2003-10-28
AU2002245385B2 (en) 2007-01-18
SK10632003A3 (sk) 2004-06-08
TR200705146T1 (tr) 2008-02-21
LT5143B (lt) 2004-06-25
EE200300419A (et) 2004-02-16
DK200301267A (da) 2003-11-06
ES2201942A1 (es) 2004-03-16
CN1229331C (zh) 2005-11-30
CZ20032380A3 (en) 2004-03-17
PL363840A1 (pl) 2004-11-29
AT414238B (de) 2006-10-15
ATA90422002A (de) 2006-01-15
HUP0303341A3 (en) 2007-03-28
SE0302361D0 (sv) 2003-09-03
LV13119B (en) 2004-06-20
IL157779A0 (en) 2004-03-28
ZA200306882B (en) 2004-12-03
NZ527431A (en) 2005-05-27
GB0323169D0 (en) 2003-11-05
LT2003075A (en) 2004-03-25
NO20033921D0 (no) 2003-09-04
US20050209341A1 (en) 2005-09-22
SE0302361L (sv) 2003-09-03
EA200300978A1 (ru) 2004-02-26
KR20030092012A (ko) 2003-12-03
EP1379492A1 (en) 2004-01-14
WO2002070457A8 (en) 2004-06-03
ES2305221T3 (es) 2008-11-01
ATE396170T1 (de) 2008-06-15
JP2004525912A (ja) 2004-08-26
CA2440161A1 (en) 2002-09-12
WO2002070457A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
MY136892A (en) Deacetylase inhibitors
CY1112487T1 (el) Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
DE60234125D1 (de) E inhibitoren
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE60007095T2 (de) Calanolide zur hemmung von btk
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
ATE424560T1 (de) Marker für neuromyelitis optica
GB2390367B (en) Lipid profile modulation
JO2242B1 (en) Phosphatase inhibitors
SE0301650D0 (sv) Novel compounds
SE0302361D0 (sv) Inhibering av upptagning av monoamin
ATE315380T1 (de) Epothilon zusammensetzungen
DE60232650D1 (de) Peptiddeformylaseinhibitoren
DOP2002000329A (es) Composicion solida
ECSP982472A (es) Compuestos calciliticos
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина
UY34598A (es) Antranilamidas insecticidas
UA50920A (uk) Опорно-центруючий пристрій
UA50440A (uk) Установка для очищення стічних вод

Legal Events

Date Code Title Description
MA Patent expired